An evidence-based approach to the evaluation and treatment of premature rupture of membranes: Part I.
Preterm premature rupture of membranes (PPROM) occurs in 3% of pregnancies and is responsible for one third of all preterm births. PPROM will affect 120,000 women in the United States each year. It is associated with significant maternal, fetal, and neonatal morbidity and mortality resulting from infection, umbilical cord compression, abruptio placentae, and prematurity. The etiology is multifactorial, but the most significant risk factors are previous preterm birth and previous preterm premature rupture of membranes. Accurate diagnosis is extremely important to assure proper treatment. Evaluation is based on patient history and clinical examination. This review presents the available evidence and grades it according to the U.S. Preventative Task Force recommendations. In part I of this review, the definition, pathophysiology, and methods of PPROM diagnosis are presented. In part II, the management, treatment, neonatal outcome, and the maternal and fetal evaluation of women with PPROM in the presence of cerclage and medical complications is reviewed.


OBJECTIVE
After completion of this article, the reader should be able to define the term: preterm premature rupture of membranes, to list the factors associated with premature rupture of membranes, and to outline the tests available for the diagnosis of intra-amniotic infection.
Magee Womens Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. tcanavan@mail.magee.edu
Timothy P
TP
Canavan
Hyagriv N
HN
Simhan
Steve
S
Caritis
D000649:Amniocentesis; D015415:Biomarkers; D002821:Chorioamnionitis / Q000175:diagnosis / Q000628:therapy; D019317:Evidence-Based Medicine; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D010808:Physical Examination; D011247:Pregnancy; D012307:Risk Factors; D012680:Sensitivity and Specificity
D015415:Biomarkers